ZYDPLA 1

Drug Profile

ZYDPLA 1

Alternative Names: ZYDPLA-1

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zydus Cadila
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 11 Aug 2017 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO) (Zydus Cadila pipeline, August 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 08 Oct 2015 ZYDPLA 1 is still in phase I trials for Type-2 diabetes mellitus in USA (Zydus pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top